News Headlines

  1. Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities 9/10/2025

    Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

  2. NKGen Biotech, Inc. Announces Completion Of NKMax Co., Ltd. Acquisition; Gains Full Control Of Global Manufacturing And Intellectual Property Assets 9/9/2025

    NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the successful completion of its acquisition of a majority equity stake in NKMax Co., Ltd. (“NKMax”), a Korean biotechnology company, out of bankruptcy.

  3. GBI Biomanufacturing Partners With NanoRetinal To Advance Vision-Restoring Therapy For Inherited Retinal Diseases 9/9/2025

    GBI Biomanufacturing (GBI), a leading US-based contract development and manufacturing organization (CDMO), is pleased to announce a partnership with NanoRetinal, Inc. to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (IRD).

  4. Kytopen Announces Collaboration With BlueWhale Bio To Revolutionize Cell Therapy Manufacturing 9/9/2025

    Kytopen Corp., a leader in providing continuous flow cellular engineering technologies, announced today its collaboration with BlueWhale Bio, Inc., a company dedicated to accelerating the growth and adoption of cell-based therapies by transforming the manufacturing process of immune cell therapies.

  5. Wheeler Bio And Pharmefex Consulting Announce Strategic Partnership To Integrate IND Drafting And CMC Support Into Wheeler's ModularCMC™ Platform 9/9/2025

    Wheeler Bio, Inc., a U.S.-based contract development and biomanufacturing organization (CDMO), today announced it has established a strategic partnership with Pharmefex Consulting, an expert CMC consultancy with deep expertise in regulatory strategy and technical operations, focused on accelerating client success in Investigational New Drug (IND) filings and regulatory submissions.

  6. Kenox Enters Into Strategic Product Development Partnership With Strides 9/9/2025

    Strides Pharma Science Ltd today announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. ("Kenox"), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).

  7. Almac Group Expands Bioavailability Enhancement Capabilities – Addressing A Critical Need In Drug Development 9/9/2025

    Almac Group has completed a multi-million-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK.

  8. Evonik And Ethris Enter Strategic Partnership To Expand Offerings For Nucleic Acid Delivery 9/9/2025

    Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, have entered into a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery.

  9. ScaleReady Awards G-Rex® Grants To Support Cell And Gene Therapy Manufacturing In California 9/9/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network (INFR5) program.

  10. KBI Biopharma, Inc. Announces Collaboration With Infinimmune Inc. To Support Antibody Manufacturing 9/8/2025

    KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first antibody discovery and design, announced a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (“IFX-101”) program.